Characterization for the Similarity Assessment between Proposed Biosimilar SB12 and Eculizumab Reference Product Using a State-of-the-Art Analytical Method

BACKGROUND: SB12 is being developed as a proposed biosimilar to eculizumab reference product (RP), a humanized monoclonal antibody (IgG2/4 kappa immunoglobulin) that binds to the human C5 complement protein. Binding to this protein inhibits complement-mediated intravascular hemolysis by blocking its...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Hyunsoo, Hong, Eunkyoung, Lee, Jungmin, Hong, Seokku, Kim, Jihye, Cho, Miju, Kim, Yikwon, Yoo, Taekyung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10287819/
https://www.ncbi.nlm.nih.gov/pubmed/37060541
http://dx.doi.org/10.1007/s40259-023-00591-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10287819/
https://www.ncbi.nlm.nih.gov/pubmed/37060541
http://dx.doi.org/10.1007/s40259-023-00591-9

Ejemplares similares